One of the most commonly amplified genes in human cancer, MCL-1, has been shown to be either amplified at the genomic level or over-expressed in a significant fraction of DLBCL patients, making it an important candidate for therapeutic targeting particularly in patients who fail on R-CHOP8,14. Here, MCL1 is linked to cancer.